日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study

类风湿关节炎患者皮下注射阿巴西普联合或不联合背景甲氨蝶呤的免疫原性、安全性和有效性:一项国际性、多中心、平行组、开放标签 III 期临床研究的结果

Peter Nash, Sauithree Nayiager, Mark C Genovese, Alan J Kivitz, Kurt Oelke, Charles Ludivico, William Palmer, Cristian Rodriguez, Ingrid Delaet, Ayanbola Elegbe, Michael Corbo

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

既往接受过英夫利昔单抗或阿巴西普治疗的类风湿性关节炎患者对阿巴西普的临床反应和耐受性:ATTEST 研究的开放标签扩展研究

Schiff, Michael; Keiserman, Mauro; Codding, Christine; Songcharoen, Suthin; Berman, Alberto; Nayiager, Sauithree; Saldate, Cristina; Aranda, Richard; Becker, Jean-Claude; Nys, Marleen; le Bars, Manuela; Reed, Diane Moniz; Poncet, Coralie; Dougados, Maxime